MTP-PE/MF59 [clinicaltrials_resource:36c65a32bf192718c8b5fb92459f2c5c]
A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only) [clinicaltrials:NCT00000958]A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 [clinicaltrials:NCT00000972]Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant [clinicaltrials:NCT00001019]A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals [clinicaltrials:NCT00001042]
intervention [clinicaltrials_vocabulary:intervention]
MTP-PE/MF59 [clinicaltrials_resource:36c65a32bf192718c8b5fb92459f2c5c]
Bio2RDF identifier
36c65a32bf192718c8b5fb92459f2c5c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:36c65a32bf192718c8b5fb92459f2c5c
intervention name [clinicaltrials_vocabulary:intervention-name]
MTP-PE/MF59
identifier
clinicaltrials_resource:36c65a32bf192718c8b5fb92459f2c5c
title
MTP-PE/MF59
@en
type
label
MTP-PE/MF59 [clinicaltrials_resource:36c65a32bf192718c8b5fb92459f2c5c]
@en